Spyre Therapeutics (SYRE) Stock Forecast & Price Target

$82.29 -10.43 (-11.25%)

As of 11:01 AM Eastern

Compare

Spyre Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
1

Hold
1

Buy
14

Based on 16 Wall Street analysts who have issued ratings for Spyre Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 1 has given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for SYRE.

Consensus Price Target

$109.71
33.33% Upside

According to the 16 analysts' twelve-month price targets for Spyre Therapeutics, the average price target is $109.71. The highest price target for SYRE is $130.00, while the lowest price target for SYRE is $80.00. The average price target represents a forecasted upside of 33.33% from the current price of $82.29.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SYRE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Spyre Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYRE Analyst Ratings Over Time

Type	Current Forecast 10/6/25 to 10/6/26	1 Month Ago 9/6/25 to 9/6/26	3 Months Ago 7/8/25 to 7/8/26	1 Year Ago 10/6/24 to 10/6/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)	6 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$109.71	$109.69	$95.83	$54.29
Forecasted Upside	33.33% Upside	23.28% Upside	0.45% Upside	225.65% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Buy

SYRE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYRE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Spyre Therapeutics Stock vs. The Competition

Type	Spyre Therapeutics	Healthcare Companies	Broader Market
Consensus Rating Score	2.88	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	18.33% Upside	866.99% Upside	20.68% Upside
News Sentiment Rating	Neutral News See Recent SYRE News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/1/2026	BTIG Research 3 of 5 stars	Julian Harrison 5 of 5 stars	Reiterated Rating	Buy	$121.00	+32.47%
10/1/2026	JPMorgan Chase & Co. 3 of 5 stars	Hardik Parikh Not Rated	Initiated Coverage	Overweight	$110.00	+23.55%
9/9/2026	Wedbush 5 of 5 stars	David Nierengarten 5 of 5 stars	Reiterated Rating	Outperform	$123.00	+35.48%
9/1/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
8/26/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Hoang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$135.00 ➝ $127.00	+18.29%
8/5/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colleen Kusy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$120.00	+15.55%
8/5/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yanan Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$90.00 ➝ $115.00	+9.59%
8/5/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$115.00 ➝ $130.00	+21.67%
7/28/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
7/13/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$84.00 ➝ $120.00	+22.77%
The case for $20,000 gold before year end (Ad) President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story. Read the full gold report and see Eifrig's top pick now
5/6/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Thompson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$92.00 ➝ $107.00	+49.24%
5/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samantha Semenkow Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$64.00 ➝ $97.00	+33.03%
4/17/2026	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debanjana Chatterjee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$64.00 ➝ $95.00	+30.63%
4/13/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Auster Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$80.00	+26.44%
4/13/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$47.00 ➝ $85.00	+32.65%
4/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$49.00 ➝ $106.00	+68.09%
2/18/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Choi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:02 AM ET.

SYRE Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Spyre Therapeutics is $109.71, with a high forecast of $130.00 and a low forecast of $80.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spyre Therapeutics in the last twelve months. There is currently 1 sell rating, 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYRE shares.

According to analysts, Spyre Therapeutics's stock has a predicted upside of 33.33% based on their 12-month stock forecasts.

Over the previous 90 days, Spyre Therapeutics's stock had 1 downgrade by analysts.

Spyre Therapeutics has been rated by research analysts at BTIG Research, Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Mizuho, Robert W. Baird, Wedbush, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like Spyre Therapeutics more than other "healthcare" companies. The consensus rating for Spyre Therapeutics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how SYRE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Spyre Therapeutics Recommendations

MarketBeat monitors more than a dozen sources for Spyre Therapeutics analyst ratings, with the most recent rating issued on 10/1/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Stock Forecast & Price Target

Spyre Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SYRE Analyst Ratings Over Time

SYRE Analyst Recommendations By Month

SYRE Price Targets by Month

Spyre Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

SYRE Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Spyre Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyre Therapeutics (SYRE) Stock Forecast & Price Target

Spyre Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SYRE Analyst Ratings Over Time

SYRE Analyst Recommendations By Month

SYRE Price Targets by Month

Spyre Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

SYRE Forecast - Frequently Asked Questions

What is Spyre Therapeutics' forecast for 2026?

Should I buy or sell Spyre Therapeutics stock right now?

Does Spyre Therapeutics's stock price have much upside?

Has Spyre Therapeutics been downgraded by Wall Street analysts recently?

What analysts cover Spyre Therapeutics?

Do Wall Street analysts like Spyre Therapeutics more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Spyre Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools